For U.S. Healthcare Professionals Only

With MenQuadfi, you canMAINTAIN THE EXISTING ACIP* MenACWY^† VACCINATION SCHEDULE^1,2

ADMINISTRATION

Primary Vaccination

• Individuals 2 years of age and older receive a single dose of MenQuadfi¹

Booster Vaccination

• A single dose of MenQuadfi may be administered to individuals 13 years of age and older who are at continued risk for meningococcal disease if at least 3 years have elapsed since a prior dose of meningococcal (groups A, C, W, Y) conjugate vaccine¹

Vaccination Following Prior Dose of Meningococcal Polysaccharide Vaccine

• A single dose of MenQuadfi may be administered if at least 3 years have elapsedsince a prior dose of meningococcal polysaccharide vaccine¹

Presentation

• MenQuadfi is supplied in 0.5-mL single-dose vials as a ready-to-use solution that does not require reconstitution¹

– Does not contain any preservatives¹

According to the CDC, 40% of adolescents in the US may be at risk of contracting meningococcal disease because they have missed their 2nd dose of MenACWY.³

Consider MenQuadfi as an option for your adolescent patients.

Purchasing considerations

Based on its distinct formulation, MenQuadfi has a unique CPT^®‡ code (90619) for billing purposes.

• MenQuadfi is available through direct purchasing channels and the Vaccines For Children (VFC) program to help keep both publicly and privately insured patients immunized

IMPORTANT SAFETY INFORMATION

MenQuadfi should not be administered to anyone who has had a severe allergic reaction to any component of the vaccine, or after a previous dose of MenQuadfi or any other tetanus toxoid-containing vaccine.

Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MenQuadfi. Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (eg, eculizumab) are at increased risk for invasive disease caused by N meningitidis, including invasive disease caused by serogroups A, C, W, and Y, even if they develop antibodies following vaccination with MenQuadfi.

Syncope can occur following, or even before, vaccination with MenQuadfi. Procedures should be in place to prevent falling and injury and to manage syncope.

Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to give MenQuadfi to persons with a history of GBS should take into account the expected benefits and potential risks.

Immunization with MenQuadfi does not substitute for routine tetanus immunization.

Vaccination with MenQuadfi may not protect all vaccine recipients.

The most common adverse reactions following a primary dose of MenQuadfi in individuals 2 years of age and older include pain at the injection site; myalgia, headache, and malaise. Other common adverse reactions in children 2 through 9 years of age include erythema and swelling at the injection site. In adolescents and adults, rates of solicited adverse reactions following a booster dose were comparable to those observed following primary vaccination. Other adverse reactions may occur.

Please see the full Prescribing Information for MenQuadfi.

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

* ACIP = Advisory Committee on Immunization Practices. ^† MenACWY = N meningitidis serogroups A, C, W, and Y. ^‡ CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

REFERENCES:

MenQuadfi [Prescribing Information]. Sanofi Pasteur Inc.
Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.
Pingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage among adolescents aged 13-17 years - National Immunization Survey-Teen, United States, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(35):1101-1108.

Back to the top